Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial

by in

Moleculin today announced that patients have successfully begun treatment in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).